EOR Blueprint Update · 2026

Women's Health / GSRH EOR: 2026 blueprint changes

The PAEA Women's Health EOR is renamed “Gynecologic, Sexual, and Reproductive Health” (GSRH) for 2026 and reorganized around anatomical/reproductive systems, with new content areas for fertility and sexual health and a new Professional Practice task area. FirstPassPA's Women's Health rotation covers this exam — including its obstetric and gynecologic content.

When it takes effect

The updated exams are effective as of July 27, 2026; legacy versions remain available through July 2027, so programs can transition on their own timeline.

A new Professional Practice task area (8%) was added to this exam (Health Maintenance is retained).

The exam was renamed from “Women's Health” to “Gynecologic, Sexual, and Reproductive Health (GSRH).”

Women's Health (GSRH) EOR blueprint: content areas (2026)

PAEA builds the GSRH End of Rotation exam on a 100-question grid: each scored question sits in one clinical content area and one task area. You will sit 120 questions, because PAEA adds 20 unscored pretest questions. These are the content areas and their published weights.

Content area (clinical)Share of the exam
Prenatal Care/Pregnancy20%
Uterine/Cervix12%
Fertility Management10%
Sexual Health/Development10%
Labor/Delivery9%
Postpartum Care8%
Breast7%
Vulva/Vaginal/Pelvic Floor7%
Psychiatric/Behavioral Health6%
Infections6%
Ovary/Adnexa5%

PAEA's GSRH blueprint (PDF) · topic list (PDF)

Task-area weightings: old vs 2026

Task areas are the medical-knowledge categories every Women's Health / GSRH EOR question is written against. Here is how they shift for 2026:

Task area (medical knowledge)Old2026
History & Physical15%15%
Diagnostic Studies10%11% ↑
Diagnosis25%20% ↓
Health Maintenance10%11% ↑
Clinical Intervention10%11% ↑
Clinical Therapeutics20%16% ↓
Scientific Concepts10%8% ↓
Professional Practicenew—8%

Biggest content-area changes

  • Renamed from “Women's Health” to “Gynecologic, Sexual, and Reproductive Health,” reorganized around anatomical/reproductive systems.
  • Fertility management — new content area at 10%.
  • Sexual health & development — new content area at 10%.
  • Psychiatric/behavioral health — new content area at 6%.
  • Top content areas: prenatal care/pregnancy 20%, uterine/cervix 12%, labor & delivery 9%, postpartum 8%, breast 7%.
  • Professional Practice added at 8%.

Try 3 free Women's Health (GSRH) EOR questions

From the free Women's Health (GSRH) EOR practice page, mapped to this blueprint. Each one shows the correct answer and a full explanation; attempt it before you reveal the answer.

Question 1ReproductiveMedium
A 30-year-old woman seeks evaluation after 14 months of regular unprotected intercourse without conception. She has no history of pelvic surgery or infection. The clinician is assessing whether ovulatory dysfunction contributes. Which menstrual history finding most strongly supports that possibility?
  • AUnpredictable periods separated by two or three months
  • BBrief pelvic pain halfway between regular periods
  • CPredictable periods recurring about every four weeks
  • DIrregular spotting between otherwise predictable periods
  • EMenstrual cramps beginning shortly before each period
Reveal answer & full explanation
Correct answer: A — Unpredictable periods separated by two or three months
  • AUnpredictable periods separated by two or three months✓
  • BBrief pelvic pain halfway between regular periods
  • CPredictable periods recurring about every four weeks
  • DIrregular spotting between otherwise predictable periods
  • EMenstrual cramps beginning shortly before each period

Why Unpredictable periods separated by two or three months is correct

  • Markedly infrequent irregular menses suggest infrequent or absent ovulation.
  • Disrupted follicular development reduces predictable release of an oocyte.
  • American Society for Reproductive Medicine 2021 fertility-evaluation guidance recognizes oligomenorrhea or amenorrhea as sufficient clinical evidence to investigate anovulation.

Why the others are wrong

  • Predictable periods recurring about every four weeks - Regular cycles in this range usually support ovulation, although exceptions exist.
  • Irregular spotting between otherwise predictable periods - Intermenstrual spotting with predictable cycles points toward a structural or cervical source, such as an endometrial polyp, or brief midcycle spotting at ovulation; the predictable cycles still support regular ovulation.
  • Menstrual cramps beginning shortly before each period - Primary menstrual cramps do not establish ovulatory dysfunction.
  • Brief pelvic pain halfway between regular periods - Brief midcycle discomfort can accompany ovulation and does not establish anovulation.

Additional high-yield points

  • Investigate underlying causes such as polycystic ovary syndrome, thyroid disease, or hypothalamic dysfunction.
  • When applicable, evaluate both partners rather than assuming the cause is exclusively female.
Question 2EndocrineMedium
A 30-year-old woman has 3 months of secondary amenorrhea and galactorrhea. She is not pregnant. Serum prolactin is 420 ng/mL and TSH is normal. MRI shows a 12 mm sellar mass. Which of the following is the most appropriate treatment?
  • ABromocriptine
  • BRadiation therapy
  • CCabergoline
  • DTranssphenoidal surgery
  • EOral contraceptives
Reveal answer & full explanation
Correct answer: C — Cabergoline
  • ABromocriptine
  • BRadiation therapy
  • CCabergoline✓
  • DTranssphenoidal surgery
  • EOral contraceptives

Why Cabergoline is correct

  • This is a macroprolactinoma (10 mm or larger) presenting with amenorrhea-galactorrhea; a prolactin above 250 ng/mL with a macroadenoma indicates a prolactin-secreting tumor rather than stalk effect from a nonfunctioning mass, which rarely raises prolactin above about 150 ng/mL
  • Medical treatment with a dopamine agonist (DA) is first-line
  • Cabergoline is preferred over bromocriptine: twice-weekly dosing, better tolerated, and higher efficacy — normalizes prolactin in most patients (over 90% with microadenomas and about 77% with macroadenomas in a large series) and shrinks most macroadenomas

Why the others are wrong

  • Bromocriptine — a dopamine agonist but less preferred than cabergoline: less effective at normalizing prolactin and shrinking the tumor, dosed one to three times daily, and less well tolerated
  • Transsphenoidal surgery — used for dopamine-agonist resistance or intolerance, pituitary apoplexy, or vision loss not responding to DA therapy; not standard first-line therapy, because a dopamine agonist is the usual initial treatment even for macroadenomas
  • Radiation therapy — reserved for refractory cases; not first-line management
  • Oral contraceptives — estrogen-progestin therapy can treat hypogonadism in a microprolactinoma when fertility is not desired, but it neither lowers prolactin nor shrinks the tumor, so a 12 mm macroadenoma needs a dopamine agonist to control tumor growth
Question 3PsychiatryMedium
A 34-year-old woman is 6 weeks postpartum after an uncomplicated vaginal delivery. She is breastfeeding exclusively. She has persistent sadness, crying spells, difficulty bonding with her infant, hopelessness, and poor sleep beyond infant care for the past 3 weeks. She denies suicidal ideation (SI). Patient Health Questionnaire-9 (PHQ-9) score is 16. Which of the following is the most appropriate management?
  • ADiscontinue breastfeeding and initiate fluoxetine
  • BTransdermal estradiol plus psychotherapy referral
  • CReassurance and watchful waiting
  • DWeekly home visits and lactation support
  • ESertraline plus psychotherapy referral
Reveal answer & full explanation
Correct answer: E — Sertraline plus psychotherapy referral
  • ADiscontinue breastfeeding and initiate fluoxetine
  • BTransdermal estradiol plus psychotherapy referral
  • CReassurance and watchful waiting
  • DWeekly home visits and lactation support
  • ESertraline plus psychotherapy referral✓

Why Sertraline plus psychotherapy referral is correct

  • This patient has postpartum depression (PPD): PHQ-9 score of 16, 3 weeks of symptoms, and difficulty bonding with her infant.
  • First-line treatment is a selective serotonin reuptake inhibitor (SSRI) plus psychotherapy (cognitive behavioral therapy (CBT)).
  • Sertraline is first-line in breastfeeding women: extensive safety data, low milk transfer.
  • Other breastfeeding-safe SSRIs include escitalopram and paroxetine.

Why the others are wrong

  • Discontinue breastfeeding and initiate fluoxetine — Discontinuing breastfeeding is not required; sertraline is safe during breastfeeding.
  • Weekly home visits and lactation support — Supportive contact and lactation help do not treat moderately severe PPD; a PHQ-9 of 16 with impaired bonding requires an antidepressant plus psychotherapy, not monitoring alone.
  • Reassurance and watchful waiting — Appropriate for postpartum blues (days 1–14, mild, self-limited); this patient's PHQ-9 of 16 and 3 weeks of impairing symptoms meet criteria for PPD and require treatment.
  • Transdermal estradiol plus psychotherapy referral — tempting because the abrupt postpartum fall in estrogen is implicated in PPD and estradiol has been studied as a treatment, but it is not a recommended therapy; estrogen may reduce milk supply in this exclusively breastfeeding mother, and an SSRI such as sertraline remains first-line pharmacotherapy alongside psychotherapy.

Additional high-yield points

  • Postpartum blues: onset days 1–14, mild, self-limited.
  • Postpartum depression (PPD): onset within the first year postpartum, PHQ-9 ≥10, persistent and impairs functioning.

That's 3 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial →

What to study now — free Women's Health / GSRH resources

Practice the areas that carry more weight in 2026. These free FirstPassPA resources are mapped to the new blueprint:

Practice the 2026 Women's Health / GSRH blueprint on FirstPassPA

Work a focused Women's Health / GSRH question set, drawn from the full 7,700+ question bank, with an AI tutor on every answer. Start your 7-day free trial — no credit card.

Start studying free → Compare PANCE question banks

Women's Health / GSRH EOR 2026 FAQ

Was the Women's Health EOR renamed?

Yes. For 2026 PAEA renamed the Women's Health EOR to “Gynecologic, Sexual, and Reproductive Health” (GSRH) and reorganized it around anatomical and reproductive systems.

What are the new content areas on the GSRH exam?

New content areas include fertility management (10%), sexual health & development (10%), and psychiatric/behavioral health (6%), plus a new 8% Professional Practice task area.

Source & disclaimer. Weightings are summarized from PAEA's publicly posted 2026 End of Rotation blueprints and crosswalk documents as of July 2026; PAEA is the authoritative source — always confirm current details there. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by PAEA or NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.